@iovance.com
Learn about our investigational tumor infiltrating lymphocyte (TIL) therapy and peripheral blood lymphocyte (PBL) therapy.
π’
Find anything inaccurate?
If you spot any mistakes on this brand profile, report to us.
Brand Logos
View allLogo
PNG
Icon
JPEG
About
Description
Iovance Biotherapeutics is a leading brand that is revolutionizing cancer treatment through its pioneering approach. Their mission is to develop and deliver tumor infiltrating lymphocyte (TIL) therapy, leveraging the power of the human immune system to recognize and attack cancer cells in each patient. With their late-stage TIL product candidate, lifileucel, they aim to create the first approved one-time cell therapy for solid tumor cancer, specifically metastatic melanoma.
Iovance's TIL platform has shown promising results in clinical trials for various solid tumors. The company is committed to continuous innovation in cell therapy, including gene-edited cell therapy, providing hope for cancer patients. As a patient-centric and collaborative organization, Iovance values integrity, agility, innovation, collaboration, and excellence in everything they do.
Their dedicated and experienced management team is at the forefront of this ground-breaking work. Please note that TIL therapy is still investigational and has not been approved by the FDA or any other regulatory agency
Company Type
Public Company
Company Size
501-1000
Year Founded
2007
Brand collections
View allLogos
Colors
Fonts
Images
Our mission is to keep every brand on-brand everywhere π
All services online
Top brand categories